{"celex_id": "32003D0427", "uri": "http://publications.europa.eu/resource/cellar/104fba11-ba99-47a9-a961-ed897d0e8cdd", "type": "Decision", "concepts": ["1270", "13", "1425", "2836", "893"], "title": "2003/427/EC: Commission Decision of 5 June 2003 authorising the placing on the market of oil rich in DHA (docosahexaenoic acid) from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document number C(2003) 1790)\n", "header": "Commission Decision\nof 5 June 2003\nauthorising the placing on the market of oil rich in DHA (docosahexaenoic acid) from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council\n(notified under document number C(2003) 1790)\n(Only the English text is authentic)\n(2003/427/EC)\nTHE COMMISSION OF THE EUROPEAN COMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Community,\nHaving regard to Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients(1), and in particular Article 7 thereof,\nHaving regard to the request by Martek Biosciences Corporation, formerly OmegaTech GmbH to the competent authorities of the United Kingdom of 13 February 2001 for placing oil rich in DHA (docosahexaenoic acid) from the microalgae Schizochytrium sp. on the market as a novel food ingredient,\nHaving regard to the initial assessment report drawn up by the competent authorities of the United Kingdom,\nWhereas:\n(1) In their initial assessment report the United Kingdom's competent food assessment body came to the conclusion that DHA-rich oil from the microalgae Schizochytrium sp. is safe for human consumption.\n(2) The Commission forwarded the initial assessment report to all Member States on 20 June 2002.\n(3) Within the 60-day period laid down in Article 6(4) of Regulation (EC) No 258/97, reasoned objections to the marketing of the product were raised in accordance with that provision.\n(4) In response to the comments and objections raised, OmegaTech GmbH amended the specifications and the applications of the DHA-rich oil. These amendments were discussed with Member States' experts on 21 October 2002.\n(5) On the basis of the initial assessment report, it is established that DHA-rich oil from the microalgae Schizochytrium sp. complies with the criteria laid down in Article 3(1) of the Regulation.\n(6) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,", "main_body": ["DHA-rich oil from the microalgae Schizochytrium sp. as specified in Annex 1, may be placed on the market in the Community as a novel food ingredient for the uses and at the maximum levels as listed in Annex 2.", "The designation \"DHA-rich oil from the microalgae Schizochytrium sp.\" shall be displayed on the labelling of the product as such or in the list of ingredients of foodstuffs containing it.", "This Decision is addressed to Martek Biosciences Corporation, 6480 Dobbin Road, Columbia, Maryland 21045 USA."], "attachments": "Done at Brussels, 5 June 2003.\nFor the Commission\nDavid Byrne\nMember of the Commission\n(1) OJ L 43, 14.2.1997, p. 1.\nANNEX 1\nSPECIFICATION OF OIL RICH IN DHA (DOCOSAHEXAENOIC ACID) OBTAINED BY HEXANE EXTRACTION OF MICROALGAE SCHIZOCHYTRIUM SP.\n>TABLE>\nANNEX 2\nUSES OF OIL RICH IN DHA (DOCOSAHEXAENOIC ACID) FROM THE MICROALGAE SCHIZOCHYTRIUM SP.\n>TABLE>\nNote:\nAll food products containing DHA-rich oil from Schizochytrium sp. should demonstrate oxidative stability by appropriate and recognised national/international test methodology (e.g. AOAC)."}